252 related articles for article (PubMed ID: 25860239)
41. Kappa and lambda light chain disease: survival rates and clinical manifestations.
Shustik C; Bergsagel DE; Pruzanski W
Blood; 1976 Jul; 48(1):41-51. PubMed ID: 820387
[TBL] [Abstract][Full Text] [Related]
42. Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma.
Migkou M; Avivi I; Gavriatopoulou M; Cohen YC; Fotiou D; Kanellias N; Ziogas D; Eleutherakis-Papaiakovou E; Terpos E; Roussou M; Kastritis E; Dimopoulos MA
Ann Hematol; 2020 Jun; 99(6):1251-1255. PubMed ID: 32307566
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.
Heaney JLJ; Campbell JP; Griffin AE; Birtwistle J; Shemar M; Child JA; Gregory WM; Cairns DA; Morgan G; Jackson G; Drayson MT
Br J Haematol; 2017 Jul; 178(2):220-230. PubMed ID: 28573706
[TBL] [Abstract][Full Text] [Related]
44. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
45. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
46. Light chain myeloma and detection of free light chains in serum and urine of dogs and cats.
Harris RA; Miller M; Donaghy D; Ashton L; Langston C; Shockey T; Moore AR
J Vet Intern Med; 2021 Mar; 35(2):1031-1040. PubMed ID: 33634914
[TBL] [Abstract][Full Text] [Related]
47. Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.
Harutyunyan NM; Vardanyan S; Ghermezi M; Gottlieb J; Berenson A; Andreu-Vieyra C; Berenson JR
Br J Haematol; 2016 Jul; 174(1):81-7. PubMed ID: 27017948
[TBL] [Abstract][Full Text] [Related]
48. Multiple narrow bands in urine protein electrophoresis.
Roach BM; Meinke JS; Sridhar N; Vladutiu AO
Clin Chem; 1999 May; 45(5):716-8. PubMed ID: 10222367
[No Abstract] [Full Text] [Related]
49. Intact and fragmented intracellular immunoglobulin in a case of non-secretory myeloma.
Whicher JT; Davies JD; Grayburn JA
J Clin Pathol; 1975 Jan; 28(1):54-9. PubMed ID: 1123437
[TBL] [Abstract][Full Text] [Related]
50. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
51. Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold.
Manohar S; Nasr SH; Leung N
Curr Hematol Malig Rep; 2018 Jun; 13(3):220-226. PubMed ID: 29725932
[TBL] [Abstract][Full Text] [Related]
52. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties.
Kaplan B; Ramirez-Alvarado M; Dispenzieri A; Zeldenrust SR; Leung N; Livneh A; Gallo G
Clin Chem Lab Med; 2008; 46(3):335-41. PubMed ID: 18254719
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis/immunofixation and the N Latex FLC assay.
Sasson SC; McGill K; Wienholt L; Carr A; Brown DA; Kelleher AD; Breit SN; Sewell WA
Pathology; 2015 Oct; 47(6):564-9. PubMed ID: 26352111
[TBL] [Abstract][Full Text] [Related]
54. [Clinical significance of measurement of free light chains].
Matsuda M
Rinsho Byori; 2010 Apr; 58(4):401-4. PubMed ID: 20496770
[TBL] [Abstract][Full Text] [Related]
55. How lab staff and the estimation of free light chains can combine to aid the diagnosis of light chain disease.
Sinclair D; Wainwright L
Clin Lab; 2007; 53(5-6):267-71. PubMed ID: 17605400
[TBL] [Abstract][Full Text] [Related]
56. Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein.
Tschautscher M; Rajkumar V; Dispenzieri A; Lacy M; Gertz M; Buadi F; Dingli D; Hwa L; Fonder A; Hobbs M; Hayman S; Zeldenrust S; Lust J; Russell S; Leung N; Kapoor P; Go R; Lin Y; Gonsalves W; Kourelis T; Warsame R; Kyle R; Kumar S
Am J Hematol; 2018 Oct; 93(10):1207-1210. PubMed ID: 30016549
[TBL] [Abstract][Full Text] [Related]
57. Value of Urinary Free Light Chain Testing for Monitoring of Bence Jones Proteinuria.
Delgado JC
J Appl Lab Med; 2019 May; 3(6):1059-1060. PubMed ID: 31639698
[No Abstract] [Full Text] [Related]
58. [Difficulties evaluating hematological response in patients with multiple myeloma and dialysis - dependent renal impairment].
Rekhtina IG; Mendeleeva LP; Soboleva NP
Ter Arkh; 2019 Jul; 91(7):70-74. PubMed ID: 32598738
[TBL] [Abstract][Full Text] [Related]
59. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder.
Vermeersch P; Van Hoovels L; Delforge M; Mariën G; Bossuyt X
Br J Haematol; 2008 Nov; 143(4):496-502. PubMed ID: 18729849
[TBL] [Abstract][Full Text] [Related]
60. Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.
Mösbauer U; Ayuk F; Schieder H; Lioznov M; Zander AR; Kröger N
Haematologica; 2007 Feb; 92(2):275-6. PubMed ID: 17296589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
